Lexaria Bioscience: Groundbreaking Research into DehydraTECH-CBD Published in Peer-Reviewed Journal

Lexaria Bioscience’s (Nasdaq: LEXX) groundbreaking research into DehydraTECH-CBD has been published in eight peer-reviewed articles in six different publications. A paper titled “Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study” was published in June 2023 in theInternational Journal of Molecular Sciences.

The company also released findings from its DehydraTECH-CBD diabetes animal study which demonstrated a 19.9% reduction in blood glucose levels and improvements in kidney function.

Highlights 

John Docherty, President of Lexaria, “Lexaria is establishing itself as one of the world’s leaders in the investigation of cannabidiol for the purposes of controlling human blood pressure and we are now focused on launching a FDA-registered IND program to formally investigate DehydraTECH-CBD for hypertension this year.”

Lexaria’s leading research into the effects of DehydraTECH-CBD upon human health, including hypertension, has been published in the journals Advances in Therapy, the Journal of Personalized Medicine, Pharmaceuticals, Cannabis and Cannabinoid Research, and Biomedicine & Pharmacotherapy.

This month, Lexaria also announced it has received a total of 6 new granted patents in 2023. The company now holds 34 granted patents worldwide.

About Lexaria Bioscience 

Lexaria Bioscience’s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients enter the bloodstream through oral delivery. DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 34 patents granted and many patents pending worldwide.

Disclaimer

This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article

 

About the Author

Lexaria Bioscience: Groundbreaking Research into DehydraTECH-CBD Published in  Peer-Reviewed Journal

Editor Prism MarketView